Weighty questions: The Tipline for 25 April 2024

Senator Bernie Sanders is targeting Novo Nordisk’s steep price tags for Ozempic and Wegovy. Announced on Wednesday, Sanders is investigating, among other things, whether the pharmaceutical company may have improperly listed patents in the Orange Book to delay generic competition for its blockbuster weight loss and diabetes drugs. Also in Tipline, Federal Trade Commission chair Lina Khan questions whether artificial intelligence could also lead to price-fixing in healthcare.